Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 3, 2009, Pages 325-332

  Heer, Tobias ^a   Juenger, Claus ^b   Gitt, Anselm K ^b   Bauer, Timm ^b   Towae, Frank ^b   Zahn, Ralf ^b   Senges, Jochen ^c   Zeymer, Uwe ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute coronary syndrome; Clinical practice; Clopidogrel; Enoxaparin; Primary percutaneous coronary intervention; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GROUPS BY AGE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; DRUG EVALUATION; DRUG THERAPY, COMBINATION; DRUG TOXICITY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RETROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 70349096856     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0294-y     Document Type: Article

References (25)

1. Wong GC, Giugliano RP, Antman EM (2003) Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 289(3):331-342. doi: 10.1001/ jama.289.3.331
2. Giugliano RP, Braunwald E (2005) The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 46:906-919. doi: 10.1016/ j.jacc.2005.06.051
3. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W, Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology (2002) Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23(23):1809-1840. doi: 10.1053/euhj.2002.3385
4. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI (2004) Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):576S-599S. doi: 10.1378/chest.126.3_suppl.576S
5. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM (2004) Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overview. JAMA 292(1):89-96. doi: 10.1001/jama.292.1.89
6. Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ (2005) A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. Am Heart J 149(4 Suppl):S91-S99. doi: 10.1016/j.ahj.2005.02.021
7. Alpert JS, Budaj AJ, Gurfinkel EP, Henry TD (2001) Issues in antithrombin therapy for UA/NSTEMI. Eur Heart J 3(Suppl J):J15-J23. doi: 10.1016/S1520-765X(01)90136-1
8. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KA (2003) Clopidogrel in unstable angina to prevent Recurrent Events Trial Investigators early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107(7):966-972. doi: 10.1161/01.CIR.0000051362.96946.15
9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G fox KK for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502. doi: 10.1056/NEJMoa010746
10. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH (2004) Antithrombotic therapy for coronary artery disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):513S-548S. doi: 10.1378/ chest.126.3_suppl.513S
11. Walsh SJ, Spence MS, Crossman D, Adgey AA (2005) Clopidogrel in non-ST segment elevation acute coronary syndromes: An overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Heart 91(9):1135-1140. doi: 10.1136/hrt.2004.051722
12. Heer T, Zeymer U, Juenger C, Gitt AK, Wienbergen H, Zahn R, Gottwik M, Senges J for the Acute Coronary Syndromes (ACOS) registry investigators (2006) Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice. Heart 92:1484-1489. doi: 10.1136/ hrt.2005.085456
13. Zeymer U, Gitt AK, Juenger C, Heer T, Wienbergen H, Koeth O, Bauer T, Mark B, Zahn R, Gottwik M, Senges J for the Acute Coronary Syndromes (ACOS) registry investigators (2006) Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 27(22):2661-2666. doi: 10.1093/eurheartj/ehl317
14. Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Le Iouer V, Fromell GJ, Demers C, Turpie AG, Califf RM, Fox KA, Langer A for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) study group (2000) Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and safety of subcutaneous enoxaparin in Non-Q wave coronary events. J Am Coll Cardiol 36(3):693-698. doi: 10.1016/S0735-1097(00)00808-1
15. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452. doi: 10.1056/NEJM199708143370702
16. Blazing MA, de Lemos JA, White HD, Fox KAA, Verheugt FWA, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM for the A to Z Investigators (2004) Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial. JAMA 292:55-64. doi: 10.1001/jama.292.1.55
17. Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ III, Califf RM, SYNERGY Trial Investigators (2005) High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: Outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 294(20):2594-2600. doi: 10.1001/jama.294.20.2594
18. The SYNERGY Trial Investigators (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy primary results of the SYNERGY randomized trial. JAMA 292:45-54. doi: 10.1001/jama.292.1.45
19. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJLM, Salein D, Bayes de Luna A, Fox KAA, Lablanche J-M, Radley D, Premmereur J, Braunwald E for the TIMI 11B Investigators (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Circulation 100:1593-1601
20. Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F on behalf of the ACUTE II Investigators (2002) Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. Am Heart J 144:470-477. doi: 10.1067/mhj.2002.126115
21. Shaun G, Goodman, Fitchett D, Armstrong PW, Tan M, Langer A for the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators (2003) Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107:238-244. doi: 10.1161/ 01.CIR.0000050144.67910.13
22. Yang X, Alexander KP, Chen AY, Reo MT, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED for the CRUSADE investigators (2005) The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE national quality improvement initiative. J Am Coll Cardiol 46:1490-1495. doi: 10.1016/j.jacc.2005.06.072
23. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774-782. doi: 10.1161/ CIRCULATIONAHA.106.612812
24. Sabatine MS, Morrow DA, Dalby A, Pfisterer M, Duris T, Lopez-Sendon J, Murphy SA, Gao R, Antman EM, Braunwald E for the ExTRACT-TIMI 25 Investigators (2007) Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol 49:2256-2263. doi: 10.1016/j.jacc.2007.01.092
25. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED for the CRUSADE investigators (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294(24):3108-3116. doi: 10.1001/jama.294.24.3108